CD34 + cell enrichment depletes atypical CD30 + cells from PBPC grafts in patients with HD

References

• Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and autologous hematopoietic progenitor cell transplanta-tion for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801–13.
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH et al. Dose intensifi-cation with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051–4.
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Taghipour G, Milligan D et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997;20:745–52.
   Google Scholar
• Yuen AR, Rosenberg SA, Hoppe RT et al. Comparison between conventional salvage therapy and high-dose ther-apy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997;89:814–22.
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Anderson JR, Freeman MB et al. High-dose chemotherapy followed by autologous hematopoietic res-cue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Onco/ 1996;7:151–6.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell trans-plantation versus autologous bone-marrow transplantation in lymphoma patients [see comments] [published erratum appears in Lancet 1996;347:914]. Lancet 1996;347:353–7.
   PubMed Web of Science ®Google Scholar
• Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow trans-plantation. Lancet 1993;341:85–6.
   PubMed Web of Science ®Google Scholar
• Rill DR, Buschle M, Foreman NK et al. Retrovirus-mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation. Hum Gene Ther 1992;3:129–36.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma [see com-ments]. N Engl .7 Med 1991;325:1525–33.
   PubMed Web of Science ®Google Scholar
• Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments]. Blood 1994;83:636–40.
   PubMed Web of Science ®Google Scholar
• Kvalheim G, Erikstein B, Gilen E et al. The presence of mikrometastases in bone marrow and blood in high-risk stage II breast cancer patients before and after high-dose therapy. In: Dicke KA, Keating A, editors. Autologous blood and marrow transplantation, Proceedings of the Ninth International Symposium, Arlington, Texas. Charlottesville, Virginia, USA: Carden Jennings Publishing, 1999:247–55.
   Google Scholar
• Dreger P, Viehmann K, von-Neuhoff N et al. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradi-cation, reconstitution of hematopoiesis and immune recovery. Bone Marrow Transplant 1999;24:153–61.
   PubMed Web of Science ®Google Scholar
• Voso MT, Hohaus S, Moos M et al. Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Br y Haematol 1999;104:382–91.
   PubMed Web of Science ®Google Scholar
• Kvalheim G, Holte H, Jakobsen E et al. Immunomagnetic purging of lymphoma cells from autografts. 7 Hematother 1996;561–2.
   Google Scholar
• Wolf J, Kapp U, Bohlen H et al. Peripheral blood mononu-clear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin—Reed Sternberg cells. Blood 1996;87:3418–28.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Podda A, Prolla G et al. CD30 in normal and neo-plastic cells. Clin Immunol 1999;90:157–64.
   PubMed Web of Science ®Google Scholar
• Sharp JG, Mann SL, Murphy B et al. Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: a review. yHematother 1995;4:141–8.
   PubMedGoogle Scholar
• Sharp JG, Kessinger A, Pirruccello SJ et al. Frequency of detection of suspected lymphoma cells in peripheral blood stem cell collections. In: Dicke KA, Armitage JO, editors. ABMT V1991:801–10.
   Google Scholar
• Sharp JG, Chan WC. Detection and relevance of minimal disease in lymphomas. Cancer Metastasis Revs 1999;18: 127–42.
   PubMed Web of Science ®Google Scholar
• Sharp JG, Kessinger A, Armitage JO et al. Clinical signifi-cance of occult tumor contamination of hematopoietic harvests in non-Hodgkin's lymphoma and Hodgkin's dis-ease. In: Zander AR, Barlogie B, editors. Autologous bone marrow transplantation fir Hodgkin's disease, non-Hodgkin's lym-phoma and multiple myeloma. Berlin: Springer, 1993:123–32.
   Google Scholar
• Majolino I, Pearce R, Taghipour G et al. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lym-phomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. 7 Clin Oncol 1997;15: 509–17.
   Google Scholar
• Perry AR, Peniket AJ, Watts MJ et al. Peripheral blood stem cell versus autologous bone marrow transplantation for Hodgkin's disease: equivalent survival outcome in a single-centre matched-pair analysis. Br y Haematol 1999;105:280–7.
   Google Scholar
• Nadali G, Tavecchia L, Zanolin E et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998;91:3011–16.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H et al. A revised European—American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood 1994;84:1361–92.
   PubMed Web of Science ®Google Scholar
• Aurlien E, Holte H, Pharo A et al. Combination chemother-apy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998;21:873–8.
   PubMed Web of Science ®Google Scholar
• Dreger P, Marquardt P, Haferlach T et al. Effective mobilisa-tion of peripheral blood progenitor cells with `Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. Br .7 Cancer 1993;68: 950–7.
   Google Scholar
• Johnsen HE, Knudsen LM. Nordic flow cytometry stan-dards for CD34+ cell enumeration in blood and leukapheresis products: report from the second Nordic Workshop. Nordic Stem Cell Laboratory Group (NSCL-G). y Hematother 1996;5:237–45.
   PubMedGoogle Scholar
• Hohmann A, Hodgson AJ, Di W et al. Monoclonal alkaline phosphatase-anti-alkaline phosphatase (APAAP) complex: production of antibody, optimization of activity, and use in immunostaining. 7 Histochem Cytochem 1988;36:137–43.
   Google Scholar
• Drexler HG. Recent results on the biology of Hodgkin and Reed—Sternberg cells. II. Continuous cell lines. Leuk Lymph 1993;9:1–25.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. y Am Stat Assoc 1958;53:457–81.
   Google Scholar
• Lakota J. Use of selected CD34+ cells in the treatment of relapsed Hodgkin's lymphoma. Bone Marrow Transplant 1999;24:697–9.
   Google Scholar
• Linch DC, Milligan DW, Winfield DA et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial [see comments]. Br y Haematol 1997;99:933–8.
   PubMed Web of Science ®Google Scholar
• Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraft-ment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. y Clin Oncol 1995;13:1323–7.
   PubMed Web of Science ®Google Scholar
• Mapara MY, Korner IJ, Hildebrandt M et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997;89:337–94.
   PubMed Web of Science ®Google Scholar